Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides

Clinical Pharmacokinetics

Volumn 52, Issue 10, 2013, Pages 855-868

  Diao, Lei ^a,b   Meibohm, Bernd ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIBODY; CETRORELIX; CYCLOSPORIN; DEGARELIX; DESMOPRESSIN; EXENDIN 4; IPAMORELIN; LEUPRORELIN; LIRAGLUTIDE; NAFARELIN; PEGINESATIDE; PEPTIDASE; PEPTIDE DERIVATIVE; POLYMER; PROTEINASE; ROMIPLOSTIM; TESAMORELIN;

AMINO ACID SUBSTITUTION; DIFFUSION; DISTRIBUTION VOLUME; DISULFIDE BOND; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; EXTRACELLULAR FLUID; EXTRAVASATION; GLOMERULUS FILTRATION; IMMUNOGENICITY; KIDNEY METABOLISM; MACROMOLECULE; MOLECULAR WEIGHT; PERMEABILITY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; REVIEW;

ANIMALS; HUMANS; IMMUNOMODULATION; PEPTIDES;

EID: 84885229737     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0079-0     Document Type: Review

References (94)

1. Vlieghe P, Lisowski V, Martinez J, et al. Synthetic therapeutic peptides: science and market. Drug Discov Today. 2010;15(1-2):40-56.
2. Sato AK, Viswanathan M, Kent RB, et al. Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol. 2006;17(6):638-42.
3. Latham PW. Therapeutic peptides revisited. Nat Biotechnol. 1999;17(8):755-7.
4. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes. 2004;53(9):2181-9.
5. Zhao L, Ji P, Li Z, et al. The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model. J Clin Pharmacol. 2013;53(3):314-25.
6. Meibohm B, Braeckman R. Pharmacokinetics and pharmacodynamics of peptide and protein drugs. In: Crommelin DJA, Sindelar RD, Meibohm B, editors. Pharmaceutical biotechnology. New York: Informa Healthcare; 2008. p. 95-123.
7. Lin JH. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Curr Drug Metab. 2009;10(7):661-91.
8. Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012;14(3):559-70.
9. Porter CJ, Edwards GA, Charman SA. Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Adv Drug Deliv Rev. 2001;50(1-2):157-71.
10. Yanez JA, Remsberg CM, Sayre CL, et al. Flip-flop pharmacokinetics- delivering a reversal of disposition: challenges and opportunities during drug development. Ther Deliv. 2011;2(5):643-72.
11. Nagaraja NV, Pechstein B, Erb K, et al. Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. Clin Pharmacol Ther. 2000;68(6):617-25.
12. Jadhav PR, Agerso H, Tornoe CW, et al. Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker. J Pharmacokinet Pharmacodyn. 2006;33(5):609-34.
13. Frank T. Population pharmacokinetics of lixisenatide, a once-daily human glucagon-like peptide-1 receptor agonist, in healthy subjects and in patients with type 2 diabetes. J Pharm Drug Deliv Res. 2013;2:1. doi: 10.4172/2325-9604.1000112.
14. Handelsman DJ, Swerdloff RS. Pharmacokinetics of gonadotropin-releasing hormone and its analogs. Endocr Rev. 1986;7(1):95-105.
15. Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet. 2002;41(7):485-504.
16. Singh R, Singh S, Lillard JW. Past, present, and future technologies for oral delivery of therapeutic proteins. J Pharm Sci. 2008;97(7):2497-523.
17. Brown LR. Commercial challenges of protein drug delivery. Expert Opin Drug Deliv. 2005;2(1):29-42.
18. Mahato RI, Narang AS, Thoma L, et al. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst. 2003;20(2-3):153-214.
19. Karsdal MA, Henriksen K, Bay-Jensen AC, et al. Lessons learned from the development of oral calcitonin. J Clin Pharmacol. 2011;51(4):460-71.
20. Holt DW, Mueller EA, Kovarik JM, et al. Sandimmun neoral pharmacokinetics: impact of the new oral formulation. Transpl Proc. 1995;27(1):1434-7.
21. Binkley N, Bolognese M, Sidorowicz-Bialynicka A, et al. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res. 2012;27(8):1821-9.
22. Antosova Z, Mackova M, Kral V, et al. Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol. 2009;27(11):628-35.
23. Senel S, Kremer M, Nagy K, et al. Delivery of bioactive peptides and proteins across oral (buccal) mucosa. Curr Pharm Biotechnol. 2001;2(2):175-86.
24. Tang L, Persky AM, Hochhaus G, et al. Pharmacokinetic aspects of biotechnology products. J Pharm Sci. 2004;93(9):2184-204.
25. Tang L, Meibohm B. Pharmacokinetics of peptides and proteins. In: Meibohm B, editor. Pharmacokinetics and pharmacodynamics of biotech drugs. Weinheim: Wiley-VCH; 2006.
26. Alton KB, Kosoglou T, Baker S, et al. Disposition of 14C-eptifibatide after intravenous administration to healthy men. Clin Ther. 1998;20(2):307-23.
27. Meibohm B, Zhou H. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol. 2012;52(1 Suppl):54S-62S.
28. Lam S, See S. Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus. Cardiol Rev. 2006;14(4):205-11. doi: 10.1097/01.crd. 0000223655.16253.e4.
29. LoRusso PM, Venkatakrishnan K, Ramanathan RK, et al. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res. 2012;18(10):2954-63.
30. Hosseinimehr SJ, Tolmachev V, Orlova A. Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. Drug Discov Today. 2012;17(21-22):1224-32.
31. Vickers AE, Fischer V, Connors S, et al. Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines. Drug Metab Dispos. 1992;20(6):802-9.
32. Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol. 2006;72(1):1-10.
33. Samtani MN, Perez-Ruixo JJ, Brown KH, et al. Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects. J Clin Pharmacol. 2009;49(3):336-50.
34. Wang Y-M, Krzyzanski W, Doshi S, et al. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J. 2010;12(4):729-40.
35. Woo S, Krzyzanski W, Duliege A-M, et al. Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. J Clin Pharmacol. 2008;48(1):43-52.
36. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 2007;28(11):482-90.
37. Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 2012;14(2):296-302.
38. Rosenstock J, Balas B, Charbonnel B, et al. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes the T-emerge 2 trial. Diabetes Care. 2013;36(3):498-504.
39. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transpl. 2005;20(suppl 6):vi3-9.
40. Rosenberg AS, Worobec AS (2004) Risk-based approach to immunogenicity concerns of therapeutic protein products, part 2 - considering host specific and product specific factors impacting immunogenicity. Biopharm Int. 17(12):34-42.
41. Ho C-L, Lin Y-L, Chen W-C, et al. Comparison of the immunogenicity of wasp venom peptides with or without carbohydrate moieties. Toxicon. 1998;36(1):217-21.
42. de Serres M, Ellis B, Dillberger JE, et al. Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man. Stem Cells. 1999;17(4):203-9.
43. Kanduc D. Immunogenicity in peptide-immunotherapy: from self/nonself to similar/dissimilar sequences. In: Sigalov AB, editor. Multichain immune recognition receptor signaling: from spatiotemporal organization to human disease: from spatiotemporal organization to human disease. Advances in experimental medicine and biology, vol 640; 2008. New York: Springer, p. 198-207.
44. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov. 2006;5(12):1034-49.
45. Welch BD, Francis JN, Redman JS, et al. Design of a potent d-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol. 2010;84(21):11235-44.
46. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut. 1994;35(3 Suppl):S1-4.
47. Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351-67.
48. Reissmann T, Schally AV, Bouchard P, et al. The LHRH antagonist cetrorelix: a review. Hum Reprod Update. 2000;6(4):322-31.
49. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61.
50. Gobburu J, Agersø H, Jusko W, et al. Pharmacokinetic- pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6.
51. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43(9):1664-9.
52. Verschraegen CF, Westphalen S, Hu W, et al. Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2003;90(3):552-9.
53. Herédi-Szabó K, Murphy RF, Lovas S. Is lGnRH-III the most potent GnRH analog containing only natural amino acids that specifically inhibits the growth of human breast cancer cells? J Pept Sci. 2006;12(11):714-20.
54. Welch BD, VanDemark AP, Heroux A, et al. Potent d-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci USA. 2007;104(43):16828-33.
55. Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58.
56. Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol. 2010;649(1-3):328- 35.
57. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2(3):214-21.
58. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci. 2008;97(10):4167-83.
59. Gregoriadis G, Jain S, Papaioannou I, et al. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int J Pharm. 2005;300(1-2):125-30.
60. Schellenberger V, Wang CW, Geething NC, et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol. 2009;27(12):1186-90.
61. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001;84(Suppl 1):3-10.
62. Dumont JA, Low SC, Peters RT, et al. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. Biodrugs. 2006;20(3):151-60.
63. Wang YM, Sloey B, Wong T, et al. Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism. Pharm Res. 2011;28(8):1931-8.
64. Perez-Ruixo JJ, Krzyzanski W, Bouman-Thio E, et al. Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects. Clin Pharmacokinet. 2009;48(9):601-13.
65. Doppalapudi VR, Tryder N, Li L, et al. Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies. Bioorg Med Chem Lett. 2007;17(2):501-6.
66. Chuang VT, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res. 2002;19(5):569-77.
67. Subramanian GM, Fiscella M, Lamouse-Smith A, et al. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol. 2007;25(12):1411-9.
68. Baggio LL, Huang Q, Cao X, et al. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology. 2008;134(4):1137-47.
69. Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(12):4810-7.
70. Giannoukakis N. CJC-1131. ConjuChem. Curr Opin Investig Drugs. 2003;4(10):1245-9.
71. LaBelle JL, Katz SG, Bird GH, et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Investig. 2012;122(6):2018-31.
72. Grigoryev Y. Stapled peptide to enter human testing, but affinity questions remain. Nat Med. 2013;19(2):120.
73. Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther. 1997;35(10):401-13.
74. Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res. 1999;16(2):176-85.
75. Zhang L, Pfister M, Meibohm B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J. 2008;10(4):552-9.
76. Meibohm B, Derendorf H. Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci. 2002;91(1):18-31.
77. Meibohm B, Laer S, Panetta JC, et al. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 2005;7(2):E475-87.
78. Laer S, Barrett JS, Meibohm B. The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol. 2009;49(8):889-904.
79. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Ann Rev Pharmacol Toxicol. 2011;51(1):45-73.
80. Barrett JS, Della Casa Alberighi O, Laer S, et al. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther. 2012;92(1):40-9.
81. Thygesen P, Macheras P, Van Peer A. Physiologically-based PK/PD modelling of therapeutic macromolecules. Pharm Res. 2009;26(12):2543-50.
82. Agoram BM, Martin SW, van der Graaf PH. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discov Today. 2007;12(23-24):1018-24.
83. Tornoe CW, Agerso H, Nielsen HA, et al. Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME. J Pharmacokinet Pharmacodyn. 2004;31(6):441-61.
84. Agerso H, Ynddal L, Sogaard B, et al. Pharmacokinetic and pharmacodynamic modeling of NN703, a growth hormone secretagogue, after a single po dose to human volunteers. J Clin Pharmacol. 2001;41(2):163-9.
85. Perez-Ruixo JJ, Kimko HC, Chow AT, et al. Population cell life span models for effects of drugs following indirect mechanisms of action. J Pharmacokinet Pharmacodyn. 2005;32(5-6):767-93.
86. Friberg LE, Henningsson A, Maas H, et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002;20(24):4713-21.
87. Budha NR, Kovar A, Meibohm B. Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects. AAPS J. 2011;13(4):650-61.
88. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet. 1986;11(2):107-32.
89. Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol. 2003;43(6):555-64.
90. Argenti D, Ireland D, Heald DL. A pharmacokinetic and pharmacodynamic comparison of desmopressin administered as whole, chewed and crushed tablets, and as an oral solution. J Urol. 2001;165(5):1446-51.
91. Gao W, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. J Pharmacol Exp Ther. 2011;336(3):881-90.
92. Agerso H, Vicini P. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Eur J Pharm Sci. 2003;19(2-3):141-50.
93. Roblitz S, Stotzel C, Deuflhard P, et al. A mathematical model of the human menstrual cycle for the administration of GnRH analogues. J Theor Biol. 2013;321:8-27.
94. Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-8.